IRON Disc Medicine Inc

$IRON 115% of the shares are owned by institutions. Shorts putting heavy pressure here because they are losing so much money. Should move over $100.00 today. JMO

$IRON Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

$IRON Disc Medicine, a clinical-stage blood-disease biotech: its 183-patient Phase 3 of bitopertin in EPP, a sunlight-pain disorder, cut blood PPIX 41.4% and added 12.2 pain-free hours in light in month 6 vs placebo. The FDA had issued a CRL on bitopertin and agreed APOLLO could serve as the basis for the response. Market value ~$2.18B at $56.84 (16:00 ET Oct 16, 2026); $717.7M cash and investments at June 30. Against: dizziness hit 50% on drug vs 11% on placebo. NDA resubmission by end-2026; FDA decision expected by mid-2027.

$IRON it probably settles in the $90 to $100+ region until PT’s are raised to reflect the phase 3 positive results

If you want to catch the next monster runner, keep UPLD on watch. UPLD just sitting at 2M float, double digit potential. Haven't seen a better ticker than UPLD in smallcap a while, this is a gem! $IRON $AAME $NVDA $SPY /..1

$IRON 🏥 Disc Medicine, Inc. reported positive pivotal Phase 3 APOLLO topline results for bitopertin in EPP, meeting all primary and secondary endpoints, and plans to resubmit an NDA by end-2026. Curated for market relevance

$IRON unless the short position changed over the last 14 days or so, then there is still room to run significantly here.

$IRON is dropping phase 3 news tomorrow morning Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) "today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET."

$IRON IRON is soaring, near 79.17, up about 39.67 percent, after positive Phase 3 results for bitopertin in EPP. The APOLLO trial enrolled 183 patients and met both co primary endpoints, reduced protoporphyrin IX and more time in light, plus every secondary endpoint. The PPIX reduction versus placebo was 41.4 percent, and the company reported no new safety signals, though about half of treated patients had dizziness versus 11 percent on placebo. Why it matters: the FDA issued a rejection letter in February asking to see APOLLO first. Disc plans to resubmit by the end of 2026 and expects a decision by mid 2027. Cantor Fitzgerald kept its Overweight rating and raised its target to 170 from 125. This is topline data, not an approval, so the regulatory step is still ahead. Follow me if you want more on the biotech names.

$IRON Actually, scrap this. There is 13 analysts’ consensus buy on this one with PT into $128+ prior to phase 3 top line, so I expect this to settle between $110 to $120

$IRON Congrats here Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) "Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and increased total time in light"

$IRON 8 a.m. Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

$IRON will host a webcast on Oct 19 to discuss topline Phase 3 results for bitopertin in EPP.

$IRON Shorts very bullish for company - it can exercise ATM into shorts allowing them to exit and company to raise cash at a good level without conducting an offering. When company ATM finishes this launches to fair value. High demand for company ATM right now coming from underwater shorts and institutions looking to get in off the back of the data which they would not otherwise be able to do easily due to lack of offering

$IRON This Is a Textbook Squeeze Setup All the ingredients are present ✅ Massively crowded short (21.73%, growing) ✅ Positive, decisive catalyst that invalidates short thesis (APOLLO clean sweep) ✅ High days-to-cover (14.7 days) ✅ Short Score 70+ ✅ Price being artificially suppressed below fundamental fair value ✅ Natural institutional buyer demand present (opening wick $71 → $75)

$IRON no position here, but isn’t 50% dizziness a little alarming?? I know it says mild to moderate, but still. ….

⚡ The FDA said no to $IRON's bitopertin in February. Today its Phase 3 answered the FDA's exact question. In month 6: 12.2 more pain-free hours in the sun for people with EPP, a disease where daylight burns. What it means for the FDA path and the calendar 👇

$IRON APOLLO hit both co-primaries. PPIX fell 41.4% vs placebo, and patients got 12.2 more pain-free hours in light per month in month 6. That pairing is the whole point. The FDA turned bitopertin down earlier this year saying the PPIX drop had not been clearly linked to sunlight tolerance. This trial measured both, and both hit. NDA resubmission is planned by year end, decision expected mid-2027. Dizziness showed up in 50% on drug, mild to moderate, nothing above Grade 3.

binary event lesson from this morning. $IRON jumped ~30% premarket just on the news that a Phase 3 webcast was scheduled, before any data was out. then the data came and it went to ~55%. when a stock runs into a binary readout, part of the good outcome is already in the price, so the same result can mean a smaller pop. here the data kept pushing it higher, one example, not a rule. premarket only.

$IRON up ~55% premarket, 56.84 to ~88, after the Phase 3 APOLLO readout in EPP (a sun pain disorder). company says bitopertin hit both co primary endpoints: blood PPIX down 41.4% (p<0.0001) and 12.2 more pain free hours in light per month (p=0.0010), plus all secondary endpoints. the catch: dizziness in 50% of patients on drug, mostly mild or moderate per the company. NDA resubmission planned by end of 2026. premarket quote, not a settled price.